Started 1 week, 2 days ago (2009-11-14 12:33:00)
by StephN
Thanks. I sure hope the answer is "yes."
This one on Saturday interests me:
Basic Science Panel Discussions - Ballroom B
Can We Measure Tumor Dormancy and Does it Matter?
Moderator: Tyler Curiel, MD, MPH, UT Health Science Center,
San Antonio, TX
Started 5 months, 3 weeks ago (2009-06-02 17:07:00)
by sassy
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival in Advan
http://www.businesswire.com/portal/s...tte.cacheto ken
__________________
Rhonda (Sassy)
dx age 45
DX 2/16/05
Stage IIb (at surgery)restaged IIIa
Left mast .9cm tumor 5 of 14 nodes
...
Started 1 month, 1 week ago (2009-10-15 05:58:00)
by gdpawel
A study was presented at the symposium about progress in drug selection through the use of cell-based functional profiling. It delt with the so-called "triple negative" breast cancer (TNBC), which is estrogen receptor negative (ER-),
progesterone receptor negative (RP-), and Her2 negative (H2-).
When breast cancer presents as locally advanced disease, it is customarily treated with ...
Started 1 month, 1 week ago (2009-10-14 11:36:00)
by chrisy
ASCO SF Breast Cancer meeting
I wanted to add a couple of comments on this as I was fortunate to attend this on behalf of Her2support.
Hopeful and Joe and others have done an amazing job of posting
abstracts and articles of interest which were presented at this meeting. I encourage you to look at these as there were a number of very ...
Started 1 month, 1 week ago (2009-10-14 08:20:00)
by Joe
ASCO San Francisco Breast Cancer Meeting
Here are some of the meeting Highlights
Regards
Joe
__________________
Proud webmaster to the internet's most informed, educated, COMPASSIONATE and caring group of breast cancer survivors.
Advocacy is a Passion not a Pasttime...